So how about that IMO town hall

Quote






And skips the question about a potential marketing reorganization. It’s so clearly going to happen, and we’ll be back in the TA model soon enough. The “centers of excellence” model is creating more problems than it’s solving… and wtf is content lab
 






anonymous said:
And skips the question about a potential marketing reorganization. It’s so clearly going to happen, and we’ll be back in the TA model soon enough. The “centers of excellence” model is creating more problems than it’s solving… and wtf is content lab
Click to expand...
A bunch of people with no pharma experience trying to "teach" best practices in this highly regulated environment
 
























Hoping for a restructuring, this experiment with this useless marketing center of excellence structure has run its course, can we finally show gh and her pampers, Cheez it, and twix marketing cronies the door? All this favoritism for these assclowns with zed pharma experience please this job is challenging enough without this stupid structure muddying up performance and people in COEs searching for validation
 






anonymous said:
Hoping for a restructuring, this experiment with this useless marketing center of excellence structure has run its course, can we finally show gh and her pampers, Cheez it, and twix marketing cronies the door? All this favoritism for these assclowns with zed pharma experience please this job is challenging enough without this stupid structure muddying up performance and people in COEs searching for validation
Click to expand...
The reorganization of the reorganization has been a disaster. 3+ years of turmoil and ways of working. Reality is that this supposedly innovative model only works on paper. Agree that the experiment has run its course.
 






This one Novartis is for the sake of all executives to say look at me, I’m known in all the TA’s. Nobody in cardio should be reaching out to reum and onc reps throughout their day but you brainiacs created something where infusion now deals with 25 Novartis reps trying to look oh so important. Way too many cooks in the kitchen.
 






anonymous said:
This one Novartis is for the sake of all executives to say look at me, I’m known in all the TA’s. Nobody in cardio should be reaching out to reum and onc reps throughout their day but you brainiacs created something where infusion now deals with 25 Novartis reps trying to look oh so important. Way too many cooks in the kitchen.
Click to expand...
Definitely needs to be cuts to leadership and marketing. All we see are changes and turnover to leadership over the past 4 years. Way too many VPs, EDs, RDs, ADs, and ABLs. Company should take a more streamlined approach in each TA. Currently each ABL only has 6-7 reps. Number should be more like 10-12 reps/ABL. Cardio and Renal should be separate because even though they say they are together as CRM. Since combining them both again 1.5 years ago, nothing has changed, they both continue to run totally separate. Why are they launching in allergy when its not part of the 4 Main TAs?
 


















anonymous said:
Allergy is clearly immunology, one of the 4 main TAs…….
Click to expand...
Fast forward to July 4, 2025.
Entresto has a biosimiliar, so half the C.V. sales force is gone.
Lp(a) has taken a significant delay, and won't launch until middle 2027.
C.V. is left with an appallingly mismanaged Leqvio to keep the division afloat for two years.
Does Novartis eventually punt on C.V.?
Look at the pipeline, what is coming that inspires confidence?
Furthermore, they are too self-important to recognize it, but they clearly do not know what they are doing in the C.V. space, as they have destroyed their s.i.RNA and they are already off and running when it comes to destroying their ASO.
Entresto? O.K., but don't forget how they struggled with it in the beginning.
It probably won't happen, but it shouldn't come as a shock if they eventually move to three T.A.'s (maybe find a new home for renal) or find something to take the place of cardiovascular as a fourth pillar.
 












anonymous said:
Fast forward to July 4, 2025.
Entresto has a biosimiliar, so half the C.V. sales force is gone.
Lp(a) has taken a significant delay, and won't launch until middle 2027.
C.V. is left with an appallingly mismanaged Leqvio to keep the division afloat for two years.
Does Novartis eventually punt on C.V.?
Look at the pipeline, what is coming that inspires confidence?
Furthermore, they are too self-important to recognize it, but they clearly do not know what they are doing in the C.V. space, as they have destroyed their s.i.RNA and they are already off and running when it comes to destroying their ASO.
Entresto? O.K., but don't forget how they struggled with it in the beginning.
It probably won't happen, but it shouldn't come as a shock if they eventually move to three T.A.'s (maybe find a new home for renal) or find something to take the place of cardiovascular as a fourth pillar.
Click to expand...
Agree with most of what you say. Probably 30-40% of CV gone by end of summer. Definitely feels like Pelacarsen won't launch until 2027. At some point they will have to sell off or just give up on Leqvio. Not sure if they can write off the bad investment of purchasing Medicines Co. Maybe CRM with just become Renal.
 






anonymous said:
They will stay in CV but they will run it really well this time.
Click to expand...
Because they deliberately ran it like shit this time?
The people who hired this coterie of idiots aren't going anywhere, so why would you expect something different?
It is a systemically rotten division and it will take dramatic, sweeping changes to fix it.
Top to bottom, its horrifically dysfunctional.
Since nobody shows any interest in doing what is glaringly necessary, continue to expect the absolute worst.
 






Top Bottom
Back
Quote